LB Pharma hires Susan Kozauer as CMO

New York, USA-based neuropsychiatric firm LB Pharmaceuticals yesterdayannounced the appointment of Dr Susan Kozauer as chief medical officer (CMO).

Dr Kozauer is a leader in neuropsychiatric drug development with more than two decades of development expertise spanning early-stage clinical studies through regulatory approval. She brings extensive experience across indications such as schizophrenia, mood disorders, and behavioral manifestations of neurodegenerative diseases. During her tenure at Intra-Cellular Therapies Dr Kozauer oversaw the clinical development of multiple compounds, including the US and global late-stage development of Caplyta (lumateperone) in adult and pediatric indications.